214 related articles for article (PubMed ID: 11402087)
1. Practical guidelines for the use of NESP in treating renal anaemia.
Aljama P; Bommer J; Canaud B; Carrera F; Eckardt KU; Hörl WH; Krediet RT; Locatelli F; Macdougall IC; Wikström B;
Nephrol Dial Transplant; 2001; 16 Suppl 3():22-8. PubMed ID: 11402087
[No Abstract] [Full Text] [Related]
2. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis.
Macdougall IC; Matcham J; Gray SJ;
Nephrol Dial Transplant; 2003 Mar; 18(3):576-81. PubMed ID: 12584282
[TBL] [Abstract][Full Text] [Related]
3. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP).
Macdougall IC
Nephrol Dial Transplant; 2001; 16 Suppl 3():14-21. PubMed ID: 11402086
[TBL] [Abstract][Full Text] [Related]
4. Improved haemoglobin concentrations with IV darbepoetin alfa--case studies of haemodialysis patients.
Thiele A; Wittner M
Curr Med Res Opin; 2002; 18(7):440-4. PubMed ID: 12487509
[TBL] [Abstract][Full Text] [Related]
5. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological and clinical profiles of long-lasting erythropoiesis-stimulating agent (darbepoetin alfa; NESP].
Nagano N
Nihon Yakurigaku Zasshi; 2008 Apr; 131(4):291-9. PubMed ID: 18408341
[No Abstract] [Full Text] [Related]
7. [Advances in therapy of renal anemia: darbepoetin alfa].
Schaefer R
Wien Klin Wochenschr; 2002 Dec; 114(23-24):955-7. PubMed ID: 12635460
[No Abstract] [Full Text] [Related]
8. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.
Li WY; Chu TS; Huang JW; Wu MS; Wu KD
J Formos Med Assoc; 2008 Nov; 107(11):843-50. PubMed ID: 18971153
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience with darbepoetin-alfa (Aranesp).
Locatelli F; Del Vecchio L; Marai P
Contrib Nephrol; 2002; (137):403-7. PubMed ID: 12101985
[No Abstract] [Full Text] [Related]
10. Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis.
De Palo T; Giordano M; Palumbo F; Bellantuono R; Messina G; Colella V; Caringella AD
Pediatr Nephrol; 2004 Mar; 19(3):337-40. PubMed ID: 14745634
[TBL] [Abstract][Full Text] [Related]
11. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ;
Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
[TBL] [Abstract][Full Text] [Related]
13. The clinical potential of novel erythropoiesis stimulating protein.
Sunder-Plassmann G; Hörl WH
Expert Opin Biol Ther; 2001 Jul; 1(4):733-9. PubMed ID: 11727508
[TBL] [Abstract][Full Text] [Related]
14. Darbepoetin alfa: its use in anemia associated with chronic kidney disease.
Robinson DM; Easthope SE
BioDrugs; 2005; 19(5):327-43. PubMed ID: 16207074
[TBL] [Abstract][Full Text] [Related]
15. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC;
Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin in kidney disease and type 2 diabetes.
Locatelli F; Del Vecchio L; Casartelli D
N Engl J Med; 2011 Jan; 364(4):384; author reply 385-6. PubMed ID: 21268745
[No Abstract] [Full Text] [Related]
17. [Changing the frequency of administration of darbepoetin alfa (from weekly to fortnightly) maintains the haemoglobin levels in patients undergoing peritoneal dialysis].
Bajo MA; Pérez Fontán M; Remón C; Sánchez-Tomero JA; Lladós F; Selgas R
Nefrologia; 2009; 29(2):136-42. PubMed ID: 19396319
[TBL] [Abstract][Full Text] [Related]
18. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease.
Grabe DW
Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S8-14; quiz S23-5. PubMed ID: 17591995
[TBL] [Abstract][Full Text] [Related]
19. Anemia and erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis.
Korbet SM
Kidney Int Suppl; 1993 Feb; 40():S111-9. PubMed ID: 8445832
[No Abstract] [Full Text] [Related]
20. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.
Wilhelm-Leen ER; Winkelmayer WC
Am J Kidney Dis; 2015 Jul; 66(1):69-74. PubMed ID: 25636816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
